Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors 13Zollinger-Ellison Syndrome 2Vipoma 2Somatostatinoma 2Pheochromocytoma 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Neuroendocrine 2Carcinoma, Medullary 2Carcinoid Tumor 2Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Non functioning pancreatic endocrine tumor 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia Type 1 1Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms 1Lung Neoplasms 1Insulinoma 1Glucagonoma 1Gastroenteropancreatic Neuroendocrine Tumors 1Gastrinoma 1Frailty 1Extrapancreatic Neuroendocrine Tumor 1Carcinoma, Merkel Cell 1Adrenal Cortex Neoplasms 1

Interventions

veliparib 1cabozantinib 1X-Rays 1Temozolomide 1Specimen Handling 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non functioning pancreatic endocrine tumor × Temozolomide × NET × Clear all
NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Vanderbilt-Ingram Cancer Center

Phase 1 Withdrawn
DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Data powered by HemOnc (CC BY 4.0) Colophon âš¡